<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428255</url>
  </required_header>
  <id_info>
    <org_study_id>9161.4</org_study_id>
    <nct_id>NCT04428255</nct_id>
  </id_info>
  <brief_title>A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Designed Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Weekly Subcutaneous Injection in Patients With Primary Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbour BioMed (Guangzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbour BioMed (Guangzhou) Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To select a dose and to make a decision for Phase 3 study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The onset of primary immune thrombocytopenia is thought to be increased platelet destruction
      and decreased platelet production due to anti-platelet antibodies. HBM9161 is a fully human
      anti-FcRn monoclonal antibody that can effectively remove pathogenic IgG, thereby relieving
      platelet destruction and rapidly increasing platelet counts in patients. The study will be
      conducted in a Phase 2/3 operational seamless design, with group Dose A and Dose B of HBM9161
      and a placebo group in Phase 2.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 21, 2020</start_date>
  <completion_date type="Anticipated">March 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who achieve the early response.</measure>
    <time_frame>7 weeks</time_frame>
    <description>The primary endpoint of phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve platelet count ≥ 50 × 10^9/L at least 2 times within 7 weeks.</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Immune Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>HBM9161 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBM9161 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be randomized in a 1:1:1 ratio to HBM9161 (Dose A or Dose B) or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBM9161 Dose A</intervention_name>
    <description>HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly</description>
    <arm_group_label>HBM9161 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HBM9161 Dose B</intervention_name>
    <description>HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly</description>
    <arm_group_label>HBM9161 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years of age at the screening visit, male or female.

          2. Persistent or chronic ITP whose average number of platelet at the screening visit and
             pre-dose (at least 1 day apart) is &lt; 30 × 10^9/L, and not &gt; 35 × 10^9/L for any of two
             tests. No severe bleeding within 4 weeks prior to the screening visit.

          3. Patients who have received and failed at least 1 first line of ITP therapy
             (glucocorticoids and/or intravenous gamma globulin), or who are contraindicated,
             intolerable, or refuse standard therapy.

          4. Patients will be allowed to use a stable dose of concomitant drugs for the treatment
             of ITP. e.g., glucocorticoid, danazol, immunosuppressant (azathioprine, cyclosporine
             A, mycophenolate mofetil) and eltrombopag.

        Exclusion Criteria:

          1. Other autoimmune systemic diseases other than ITP.

          2. Multi-lineage immune cytopenias, such as Evan's syndrome, autoimmune pancytopenia.

          3. Secondary ITP.

          4. Received a vaccine within 4 weeks prior to the first dose of the study drug or planned
             during the study.

          5. Use of anticoagulants or any agents that have antiplatelet effect or can affect
             thrombopoiesis within 3 weeks prior to the first dose of the study drug.

          6. Received blood transfusion within 1 week prior to the first dose of the study drug.

          7. Received the intravenous gamma globulin, anti-D immunoglobulin, or plasmapheresis
             within 2 weeks prior to the first dose of the study drug.

          8. Received high-dose dexamethasone or high-dose methylprednisolone within 2 weeks prior
             to the first dose of the study drug.

          9. Received recombinant human thrombopoietin (rhTPO) within 4 weeks prior to the first
             does of the study drug.

         10. Received rituximab or other non-rituximab anti-CD20 drugs within 6 months prior to the
             first does of the study drug.

         11. Treated with splenectomy within 4 weeks prior to first dose of the study drug.

         12. Any thromboembolic or embolic events within 12 months prior to the first does of the
             study drug.

         13. Serum total IgG &lt; 700 mg/dL at the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renchi Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology hospital, Chinese academy of medical sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuai Zhao</last_name>
    <phone>+86 15901236575</phone>
    <email>peter.zhao@harbourbiomed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology hospital, Chinese academy of medical sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Renchi Yang, doctor</last_name>
      <phone>+86 13512078851</phone>
      <email>rcyang65@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT04428255/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

